A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy

Supportive Care in Cancer

Volumn 20, Issue 8, 2012, Pages 1797-1804

  Lalla, Rajesh V ^a   Gordon, Gary B ^b,h   Schubert, Mark ^c   Silverman Jr , Sol ^d   Hutten, Mark ^e   Sonis, Stephen T ^f   LeVeque, Francis ^g   Peterson, Douglas E ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Fred Hutchinson Cancer Research Center and University of Washington ^*

^c USA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ABBOTT LABORATORIES   (United States)

Author keywords

Chemotherapy; Misoprostol; Mucositis; Prostaglandin E1

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; MISOPROSTOL; MITOXANTRONE; PACLITAXEL; PLACEBO; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LENGTH OF STAY; LYMPHOMA; MALE; MOUTH PAIN; MULTIPLE MYELOMA; ORAL MUCOSITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; UTERUS CANCER; VISUAL ANALOG SCALE;

ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LENGTH OF STAY; MALE; MISOPROSTOL; PAIN MEASUREMENT; PARENTERAL NUTRITION, TOTAL; PLACEBOS; STOMATITIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84863985248     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1277-7     Document Type: Article

References (33)

1. Barasch A, Peterson DE, Tanzer JM, D'Ambrosio JA, Nuki K, Schubert MM, Franquin JC, Clive J, Tutschka P (1995) Heliumneon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 76:2550-2556
2. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33-39
3. Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-MendivilM, Gallardo- Rincon D, Lara-Medina F, Aguilar-Ponce L, Miranda-Lopez E, Zinser-Sierra J, Reynoso-Gomez E (1996) Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized doubleblind study. Bone Marrow Transplant 17:809-812
4. Epstein JB (2007) Mucositis in the cancer patient and immunosuppressed host. Infect Dis Clin North Am 21:503-522, vii
5. Fall-Dickson JM, Ramsay ES, Castro K, Woltz P, Sportes C (2007) Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation. Clin Ther 29 (Suppl):2547-2561
6. Garris RE, Kirkwood CF (1989) Misoprostol: a prostaglandin E1 analogue. Clin Pharm 8:627-644
7. Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y(1995) Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E (1) analog: a placebo-controlled double-blind clinical trial. Am J Ther 2:850-857
8. Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y (1997) Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: a placebo controlled double blind clinical trial. Adv Exp Med Biol 400B:811-818
9. Haynes DR, Whitehouse MW, Vernon-Roberts B (1992) The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. Immunology 76:251-257
10. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14:505-515
11. Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR (1999) Association between mucositis severity and vancomycinresistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 20:660-663
12. Lalla RV, Peterson DE (2005) Oral mucositis. Dent Clin North Am 49:167-184
13. Lalla RV, Peterson DE (2006) Treatment of mucositis, including new medications. Cancer J 12:348-354
14. Lalla RV, Pilbeam CC,Walsh SJ, Sonis ST, Keefe DM, Peterson DE (2010) Role of the cyclooxygenase pathway in chemotherapyinduced oralmucositis: a pilot study. Support Care Cancer 18:95-103
15. Lalla RV, Schubert MM, Bensadoun RJ, Keefe D (2006) Antiinflammatory agents in the management of alimentary mucositis. Support Care Cancer 14:558-565
16. Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin NorthAm52:61-77
17. Mahatma M, Agrawal N, Dajani EZ, Nelson S, Nakamura C, Sitton J (1991) Misoprostol but not antacid prevents endotoxininduced gastric mucosal injury: role of tumor necrosis factoralpha. Dig Dis Sci 36:1562-1568
18. Malkinson FD, Geng L, Hanson WR (1993) Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. J Invest Dermatol 101:135S-137S
19. McGrath PA (1990) Pain in children-nature, assessment, and treatment. Guiilford Publications, New York
20. Raber-Durlacher J, Barasch A, Peterson DE, Lalla RV, Schubert MM, Fibbe WE (2004) Oral complications and management considerations in patients treated with high-dose cancer chemotherapy. Supportive Cancer Therapy 1:219-229
21. Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J, Duerst R, Abboud CN, Constine L, Andrews J, Etter MA, Spear L, Powley E, Packman CH, Rowe JM, Schwertschlag U, Bedrosian C, Liesveld JL (1999) Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17:2446-2453
22. Reimann HJ, Lewin J, Schmidt U, Wendt P, Blueml G, Dajani EZ (1987) Misoprostol prevents damage to the gastric mucosa by stabilizing the mast cells. Prostaglandins 33 (Suppl):105-116
23. Rossetti RG, Seiler CM, Brathwaite K, Zurier RB (1995) Effect of misoprostol on acute and chronic inflammation. Am J Ther 2:600-606
24. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST (1998) The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82:2275-2281
25. Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V (1996) Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study. Cancer 78:1477-1482
26. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69:2469-2477
27. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201-2205
28. Vagliano L, Feraut C, Gobetto G, Trunfio A, Errico A, Campani V, Costazza G, Mega A, Matozzo V, Berni M, Alberani F, Banfi MM, Martinelli L, Munaron S, Orlando L, Lubiato L, Leanza S, Guerrato R, Rossetti A, Messina M, Barzetti L, Satta G, Dimonte V (2011) Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT-results of a multicentre study. Bone Marrow Transplant 46:727-732
29. Vandervoort JM, Nieves MA, Fales-Williams A, Evans R, Mason DR (2006) An investigation of misoprostol in the promotion of wound healing. Vet Comp Orthop Traumatol 19:191-195
30. Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B, Tiver KW (2006) Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, doubleblind, placebo-controlled trial. Australas Radiol 50:468-474
31. Widomski D, Fretland DJ, Gasiecki AF, Collins PW (1997) The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Immunopharmacol Immunotoxicol 19:165-174
32. Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P, Gonidi M, Kouloulias V, Sotiropoulou-Lontou A, Pissakas G, Kyprianou K, Kouvaris J, Patsouris E (2008) Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer 16:1025-1033
33. Prescribing information for cytotec. Available at www.accessdata.fda.gov/ drugsatfda-docs/label/2002/19268slr037.pdf Accessed on 20 July 2011